Collegium | News

Collegium Pharmaceutical Inc. Receives FDA Fast Track Designation for Tamper Resistant, Chronic Pain Product, COL-172

- Company’s second product utilizing the DETERx™ tamper resistant, extended release technology to receive Fast Track status

CUMBERLAND, RI-- (BUSINESS WIRE)—June 10, 2010—Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of COL-172 for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. COL-172, a tamper resistant, extended release oral opioid formulation, is the Company’s second product candidate incorporating its proprietary DETERx™ technology for which it has filed an IND application. The Company’s lead product candidate, COL-003, is currently in late stage clinical development and has also been granted Fast Track Designation by the FDA.

The FDA’s Fast Track Drug Development Program is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Fast track designated products ordinarily qualify for priority review, thereby expediting the FDA review process.

The rationale for the investigation of COL-172 as a Fast Track development program stems from the well documented issues associated with the misuse and abuse of opioid products, and in particular extended-release formulations of these drugs. Extended release opioid formulations are very effective for the treatment of pain in chronic patients when used correctly and according to the product label but can be attractive targets for non-medical use, since the time-release mechanism of most currently marketed products can be defeated by chewing, crushing or dissolving the formulation in water, rendering the full dose of drug immediately available if ingested orally, snorted or injected. Such “formulation tampering” is believed to be widely prevalent. The Company’s DETERx™ delivery technology consists of a multi-particulate matrix formulation in a capsule, designed to be less susceptible than conventional formulations to common methods of tampering and physical manipulation without relying on aversive agents or pharmacological approaches that could have unintended harmful effects when used by legitimate patients.

“Extended release opioids remain a very valuable treatment option for patients who suffer from chronic pain. Our goal at Collegium is to incorporate advanced drug delivery technologies such as DETERx™ to many of the commonly available opioid compounds in order to maintain the clinical utility, while at the same time lessen the chance for misuse via tampering,” stated Michael Heffernan, President, Collegium Pharmaceutical. ”We are pleased that the FDA has recognized that our second product candidate incorporating our DETERx™ delivery technology, COL-172, may fulfill the significant public health need for a tamper resistant, extended release opioid product, as evidenced by the Fast Track designation.”

DETERx™ is a proprietary tamper resistant, extended release delivery platform that can be applied to drugs prone to abuse as well as drugs that have a narrow therapeutic window in which the inadvertent destruction of the time release system (crushing, breaking, chewing) can cause harm to a patient. The Company’s DETERx™ platform consists of a multi-particulate matrix formulation in a capsule and is covered by a patent that expires in 2025. While developed primarily to provide tamper resistant, extended release properties, the multi-particulate design has the potential to allow patients with difficulty swallowing to open the capsule and administer the contents on food or with water, while maintaining the extended release properties of the product. In addition to COL-003 and COL-172, the Company has a number of additional DETERx™ product candidates in development for the treatment of pain and other CNS disorders.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products. These products target market opportunities through formulation based product improvements protected by intellectual property (IP). Collegium is focused on building a portfolio of pain products that incorporate its patent protected DETERx™ formulation platform that provides for extended release and tamper resistance. The Company, through its subsidiary, Onset Therapeutics (www.onsettx.com), develops and commercializes products for skin and skin related disorders using its novel DELEVO® Foam Technology. For more information, visit the Company’s website at www.collegiumpharma.com.